about
Long-term costs and survival of prostate cancer: a population-based study.Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.Patients with psoriasis on a new trajectory: long-term improvement in quality of life with biologics.Is the DLQI appropriate for medical decision-making in psoriasis patients?Impact of dupilumab on health-related quality of life in patients with atopic dermatitis.Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn’s diseaseIs the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?Subjective well-being in patients with pemphigus: a path analysis.Towards a Central-Eastern European EQ-5D-3L population norm: comparing data from Hungarian, Polish and Slovenian population studies.Determinants of the acceptability of health problems in different ages: exploring a new application of the EQ VAS.A comparison of European, Polish, Slovenian and British EQ-5D-3L value sets using a Hungarian sample of 18 chronic diseases.Subjective expectations regarding ageing: a cross-sectional online population survey in Hungary.Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceusProposal of a new scoring formula for the Dermatology Life Quality Index in psoriasisLong-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-AnalysisCross-country generalizability of quality-of-life scores in atopic dermatitisPatient-assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceusTime to revise the Dermatology Life Quality Index scoring in psoriasis treatment guidelinesEQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature reviewPsychometric properties of the Hungarian version of the eHealth Literacy ScalePatient and general population values for luminal and perianal fistulising Crohn's disease health statesCost-of-illness studies in nine Central and Eastern European countriesLong-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysisValidity and reliability of the 9-item Shared Decision Making Questionnaire (SDM-Q-9) in a national survey in HungaryDLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morpheaDisease burden of patients with pemphigus from a societal perspectiveCapability of well-being: validation of the Hungarian version of the ICECAP-A and ICECAP-O questionnaires and population normative dataA new self-reported measure of disease severity of scalp hair loss in alopecia areata
P50
Q38650062-F4EE94B3-DCB6-4A3B-A90C-6CCE0B4B6DDAQ48123615-08DB4C08-39C0-4C07-B6B7-BCEC535DDDB8Q48192964-A106715A-2931-45C2-8783-1D7C0DB14226Q48320518-3B53F87A-6E30-47C8-857F-CFE4BA7A02F2Q50020711-A3ECB0E2-E998-4887-89D7-5601B79EEFBEQ57089296-5807DDF6-4E4C-4EB7-BB5E-9C043E4981E6Q64937914-7A4ACB65-8CB3-4008-B4CD-DEF985188ADCQ64944030-0FC62FC7-8B0A-46F8-813F-999A4942198EQ64968601-4045C537-F5CD-475E-8F8C-BAA18448FCDEQ64971484-EEF22659-C643-434D-A496-375FAC44DFB9Q64981700-6FE73E33-C884-4BD7-9C4D-085B74632D0BQ65001028-EAA2B777-8B65-474C-AC72-E8893ECD8652Q89089005-D15E12D9-58D6-49F8-BCF0-5EEF268F1FFAQ89397958-C1369188-8A90-42A7-8738-D7F668AF5CEFQ91021980-F110664C-565F-4123-8D07-9D1436B8BF05Q91202538-7F9DEC88-3FEA-4759-B1C3-EA915E2787D5Q91550110-CDF9D0CF-7E62-4C67-B568-D28A29D7B399Q92030253-BF34E939-3CFC-43B0-9D63-6C45C4F97EBDQ92102042-644C69D6-6978-495B-B17B-FA57D6D190E1Q92102051-F63B1030-DDA1-41F7-BA51-FDA6DCF3D4ECQ92127847-64558EF6-80C0-4DB8-8E12-35E9BBA393B3Q92139201-9A155FB9-813F-400A-B6CE-B9129143E93AQ92151206-DBC2ED1B-6FE9-489C-A14A-A1C181CDC5CFQ92180530-CD7E6B5F-A459-4933-AB9A-6A57718B9D46Q92661168-261DD3BB-0FCB-4B42-8133-CB05EB3A55A2Q92916655-F3D7712E-CA60-488A-B454-1AD9A1110B6BQ95938889-469C96DF-00A0-4671-AF5B-A1850D3F3305Q96350089-09AE3DAB-9FA6-46E7-8EFC-65C0762ACC1C
P50
description
researcher
@en
wetenschapper
@nl
name
F Rencz
@en
F Rencz
@nl
type
label
F Rencz
@en
F Rencz
@nl
prefLabel
F Rencz
@en
F Rencz
@nl
P31
P496
0000-0001-9674-620X